USSTOCK.TODAY
Regular Market
Log in Sign up

Teva Pharmaceutical Industries Receives FDA Approval for Schizophrenia Treatment

Nasdaq +2 ·

TEVA Teva- Pharmaceutical Industries Ltd
$40.21 -1.01%
View chart & analysis →
  1. 1The U.S. Food and Drug Administration has approved Weltrusa (olanzapine) extended-release injection.
  2. 2Teva Pharmaceutical Industries ADR shares rose 4.5% in premarket trading on Friday.
  3. 3The drug targets 2.1 million Americans living with schizophrenia.

So what's the key point?

The U.S. Food and Drug Administration approved Teva Pharmaceutical Industries' treatment for schizophrenia. Following this news, the stock price rose 4.5%.

Source Nasdaq +2 · View original ↗

Related 3-line summaries

FDA Approves Teva's Monthly Olanzapine Injection for Schizophrenia Pharmaceutical Technology · Oct 12Nine Mid-Size Drugmakers Agree to Cut Prices, Invest $19.6B in U.S. Factories Stocktwits +1 · Sep 1Trump expands drug pricing deal to 26 companies, adding 9 more Barrons.com +1 · Sep 1
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news